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Abstract 
 
This agreement known as the Pharmaceutical Zero-for-Zero Initiative took 
effect in 1995. Initially 22 countries agreed to eliminate tariffs on pharmaceutical 
products. Serbia has taken part in that agreement during 2007. Sectoral initiative 
in pharmaceuticals, according to the Serbian Custom Tariffs consists of 114 tariff 
lines and all products are included in Chemical Harmonization Agreement. The 
sector accounts for 3.24% of the total Serbian industry in 2006, with the value of 
sector’s annual production is € 308 million. Annual growth of the sector in 2006 
was 15%. During the period 2001 – 2006, the foreign trade of Pharmaceuticals 
was characterized by constant and growing trade deficit with the faster growth of 
imports (24.14%) than the exports (14.63%). The annual average share of those 
products in the total exports and imports accounted for 2.3%. 
 
Apstakt 
 
Sporazum koje je poznat pod nazivom „Inicijativa nula-za-nula“ je stupio na 
snagu 1995. godine. Inicijalno su se 22 zemlje dogovorile da eliminišu carinsku 
zaštitu na proizvodima farmaceutske industrije. Srbija je pristupila sporazumu 
tokom 2007. godine. Sektorska inicijativa u farmaceutskim proizvodima u skladu 
sa Carinskom tarifom Srbije se sastoji od 114 tarifnih linija i proizvoda i oni su 
svi uključeni u sporazum o harmonizaciji Hemijske industrije. Ovaj sektor čini 
3.24% ukupne proizvodnje Industrije Srbije u 2006. godini, sa vrednošću godišnje 
proizvodnje od 308 miliona evra. Godišnja stopa rasta u 2006. godini je bila 
15%. U periodu 2001-2006 spoljnotrgovinska razmena je imala stalni trend 
porasta trgovinskog deficita, sa većom stopom porasta uvoza od 24.14% u odnosu 
na stopu rasta izvoza koja je bila 14.63%. Učešće ovog sektora u ukupnoj 
spoljnotrgovinskoj razmeni Srbije se kretalo na nivou od 2.3%. 
                                                     
* Mr Jovan Zubović, Institut ekonomskih nauka, Beograd 
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Sector initiative overview  
In 1995, 22 countries1 agreed to eliminate tariffs on pharmaceutical products, 
their derivatives, and certain chemical intermediates used to manufacture 
pharmaceuticals. This agreement is known as the Pharmaceutical Zero-for-Zero 
Initiative. Since the original agreement entered into force, it has been updated 
twice, in 1997 and 1999, to expand the list of products that can be imported free 
of duty. The agreement, effective January 1st, 1995, eliminated tariffs in signatory 
countries regarding approximately 7,000 pharmaceutical products and chemical 
intermediates for all World Trade Organization members on a Most Favored 
Nation (MFN) basis In the Uruguay Round Agreements Act (URAA). 
Description of Products Covered 
Pharmaceuticals are used to prevent, diagnose, treat, or cure diseases in 
humans and animals.2 Products included in the pharmaceutical agreement include 
dosage-form pharmaceuticals, bulk pharmaceuticals, and certain chemical 
intermediates used in the production of pharmaceuticals. Dosage - form 
pharmaceuticals are formulated products in dosage forms, such as tablets or vials, 
which may be packaged for retail sale. Pharmaceuticals in dosage form are 
generally sold to the final customer as generic or brand name products, either by 
prescription or over-the-counter. Bulk pharmaceuticals are active ingredients that 
are produced or purchased by pharmaceutical firms and further processed into 
dosage-form products. The chemical intermediates covered, generally organic 
chemicals, are inputs in the production of pharmaceutical active ingredients. 
Chemical intermediates are produced by either pharmaceutical firms or specialty 
chemicals firms and usually used by pharmaceutical firms for producing bulk 
pharmaceutical products. 
Overview of the Pharmaceutical Industries in USA and EU 
Most finished pharmaceutical products and bulk active ingredients are 
manufactured by pharmaceutical companies. Chemical intermediates included in 
                                                     
1 The 22 countries were the EU-15 (Austria, Belgium, Denmark, Finland, France, 
Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, 
Sweden, and the United Kingdom), USA, Canada, the Czech Republic, Japan, Norway, 
the Slovak Republic, and Switzerland. 
2 The Pharmaceutical Zero-for-Zero Initiative applies only to pharmaceuticals for human 
use. 
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the Pharmaceutical Appendix may be produced by either pharmaceutical 
companies or by specialty chemicals firms. The closer the intermediate is to the 
final pharmaceutical product, the more likely it is to be produced by a 
pharmaceutical firm. Pharmaceutical companies may produce final and 
intermediate products by either fermentation or traditional chemical synthesis.3 
Specialty chemical companies that supply intermediates to drug companies 
generally use traditional chemical synthesis, but future advances in biotechnology 
may allow more specialty chemicals to be produced via fermentation or 
enzymatic processes. Both the pharmaceutical and chemical industries include 
large, multinational firms that often have manufacturing facilities throughout 
North America, Europe, and Asia. 
Both the U.S. chemical industry and the U.S. pharmaceutical industry spend 
large amounts of money on research and development (R&D). According to the 
Pharmaceutical Research and Manufacturers Association (PhRMA), the 
pharmaceutical industry spent 39.4 billion USD on R&D in 2005. Much of that 
spending went to the development of new drugs. The average cost of developing 
one new drug is estimated to be 800 million USD over 10 to 15 years. The largest 
portion of the money and time is spent in clinical trials, which the U.S. Food and 
Drug Administration (FDA) require to ensure the safety and efficacy of the new 
drug. Since other chemical sectors typically do not face as stringent a regulatory 
system as pharmaceutical companies, product development in these sectors is 
generally faster and less expensive. 
Patent protection is also important to the pharmaceutical industry. Usually 
firms receive exclusive rights to sell a pharmaceutical product for 20 years. 
However, depending on the length of the product approval process, the period of 
time during which the patent holder has the exclusive right to commercially 
market the product may be significantly less than 20 years. Generic drugs are 
increasingly being produced in developing countries, such as China and India, for 
internal consumption and export. 
In 2002, shipments for the chemical and allied products industry totaled 
approximately 454 billion USD; the pharmaceutical industry accounted for 31 
percent of this amount. The pharmaceutical industry also accounted for 47 percent 
of U.S. chemical imports and 24 percent of U.S. chemical exports in 2002. 
Employment in the pharmaceutical industry accounts for 30 percent of total 
employment in the chemical industry and 24 percent of its production workers. 
When a new pharmaceutical is available for human use, it is immediately 
eligible for duty-free treatment if it is classified in chapter 30, defined in part as 
                                                     
3 Fermentation is the cultivation of microorganisms for the enzymatically controlled 
production of compounds by cellular metabolism. Chemical synthesis is the formation 
of compounds from simpler compounds by chemical reaction 
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imported in dosage form and/or packaged for sale, or if it is imported as a bulk 
pharmaceutical under one of the four HS headings in chapter 29 mentioned above. 
However, if this new pharmaceutical is imported in bulk under another HS 
heading and is not already included in the Pharmaceutical Appendix, it may be 
added to the duty-free list in the appendix only after a periodic update. Most 
chemical intermediates used to make new pharmaceuticals that are not yet 
covered by the agreement would fall outside Chapter 30 and HS headings 2936, 
2937, 2939, and 2941 and would have to be added to the Pharmaceutical 
Appendix to receive duty-free treatment. 
Trade data from the period 2004 - 2005 for the products currently included in 
the Pharmaceutical Zero-for-Zero Initiative are presented in table 1, providing 
imports for consumption, domestic exports, and the trade balance for HS chapter 
30 and HS headings 2936, 2937, 2939, and 2941. 
Total trade in products classified under these subheadings was valued at more 
than 64 billion USD in 2005. Imports of these items were valued at approximately 
19.2 billion USD in 2004 and 18.8 billion USD in 2005. Bulk pharmaceutical 
active ingredients and chemical intermediates listed in the appendix are classified 
under various HTS subheadings; the tariff rates for the products range from 0 to 
6.5 percent ad valorem. Based on 2005 import data, the ad valorem equivalent 
tariff rate for the products currently in the Pharmaceutical Appendix would have 
been 6.0 percent if they had not received duty-free treatment. 
 
 
Table 1. Trade of Pharmaceuticals in US, 2004–2005 (million dollars) 
imports for 
consumption domestic exports trade balance Product 
grouping 2004 2005 2004 2005 2004 2005 
2936 644 620 424 425 -221 -195 
2937 1,720 1,697 2,405 1,879 685 181 
2939 644 336 17 135 -627 -201 
2941 1,197 1,380 1,149 1,348 -48 -32 
Chapter 30 32,245 35,574 18,934 21,059 -13,312 -14,515 
Total 36,451 39,607 22,929 24,846 -13,522 -14,761 
Source: Official statistics of the U.S. Department of Commerce. 
 
 
For the proposed additions to the Pharmaceutical Appendix, it is impossible to 
provide official trade statistics because the 8-digit classifications of goods 
included in this study cover multiple products, many of which are not included in 
the pharmaceutical agreement.  
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Table 2. Pharmaceuticals industry data in EU*(million EURO, units) 
Type 1990 1995 2000 2004 2005 
Production 60,220 87,799 121,471 160,769 170,000 
Exports 23,180 44,188 90,935 165,003 178,000 
Imports 16,113 31,018 68,841 132,853 144,000 
Trade balance 7,067 13,170 22,094 32,150 34,000 
R&D expenditure 7,766 11,484 17,849 21,106 21,700 
Employment 500,879 506,052 538,317 612,114 615,000 
(*) Data relate to EU-25, Norway and Switzerland since 2004 
Source: EFPIA member associations (official figures) - (e): EFPIA estimate; Eurostat 
(EU-25 trade data 1995-2005) 
Production in Serbia 
Generic drugs have very important role in the industry. This trend has created 
a tremendous business opportunity for pharmaceutical companies who serve the 
“bottom of the pyramid”. Serbian pharmaceutical companies have strategically 
positioned themselves to take advantage of the mentioned trends. Many of the 
Serbian pharmaceutical companies have invested substantial capital into 
development and are capable of producing quality low-cost generic drugs. If short 
of in-house manufacturing capacities, want to outsource small-batch production, 
reduce manufacturing costs, or delay/avoid capital investments in manufacturing, 
one should consider manufacturing in Serbia. 
Sectoral initiative in pharmaceuticals, according to the Serbian Custom Tariffs 
consists of 114 tariff lines. All products are included in Chemical Harmonization 
Agreement. 55 products are from chapter 29 - Organic chemicals and 59 products 
from chapter 30 - Pharmaceutical products. Comparative classification of the 4 
digit HS and ISIC rev.3 is shown in table 3. 
 
Table 3. Comparative classification of Pharmaceutical products,  
number of companies and employees in Serbia 
HS 4 digit ISIC3 classification 
Number of 
active 
companies* 
Number of 
employees* 
3001, 3002.9 24410 5 602 
2936,2937,2939,2941, all other 
30 24420 27 7214 
* Source: Serbian Chamber of Commerce, Privatization Agency of Serbia 
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All HS 4 digit product lines are clearly divided into ISIC rev.3 classification. 
Its very important to notice that 129 companies registered to ISIC3 classification 
24660 belonging to HS 3006, which employ over 2000 employees are taken out 
of consideration since 99.9% of their production belongs to Chemicals rather than 
to Pharmaceuticals. 
The largest companies in Serbia in manufacture of Pharmaceuticals are: 
Galenika, Hemofarm, Zorka Pharm, Jugoremedija, employing 2700, 1700, 600 
500 workers respectively. Galinka is state owned and the other three are private 
owned companies.  
Value of production of Galenika in 2004 was 63 million EURO which in 2005 
increased to 70 million EURO.4 At the same period, Hemofarm production 
increased from 110 to 160 million EURO.5  
The sector accounts for 3.24% of the total industry in 2004, with the value of 
sector’s annual production is EURO308 million. Annual growth of the sector in 
2004 was 15%.6 
 
 
Graph 1. Index of industrial production in pharmaceuticals in Serbia 
(previous year =100%) 
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      Source: Statistical office of Serbia 
                                                     
4 Galenika a.d., Financial Statement, http://www.galenika.co.yu 
5 Belgrade Stock Exchange, www.belex.co.yu 
6 The Association of Chemists and Chemical Engineers of Serbia, http://www.shts.org.yu 
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Companies like Hemofarm and Galenika, which have invested substantial 
capital into development, are expanding the frontiers of pharmaceutical industry 
in the Region. Other companies like the Zdravlje Actavis (owned by Actavis 
company from Iceland) which is one of the leading manufacturers of generics in 
Serbia provide access to low cost drugs. 
Hemofarm is a company with decades of experience in drug production. 
Today, the Group comprises a parent company and 21 subsidiaries, 12 in Serbia 
and the rest abroad. Galenika has been producing drugs for 60 years. It was 
established in 1945, and soon after became the fourth company in the world 
producing penicillin. In 1991 it has entered JV with ICN, which ended in 1999. 
Currently, the company accounts for 30% of the domestic market. 
Regional distribution of employment and production 
In Serbia there are 32 active companies employing 7816 people in 
pharmaceuticals production. Three of them with 2800 employees are still in state 
ownership. In analysis of regional distribution of companies, it is noticeable that 
production is concentrated in five counties: “Beograd, Južnobanatski, Mačvanski, 
Nišavski and Jablačnički” county, where 97%7 of employees working in 
pharmaceuticals production are employed. Moreover production in Podunavski 
region accounts for 57% of value added in 20058.  
                                                     
7 Serbian Chamber of Commerce, http://portal.komora.net  
8 Government of Serbia, Strategy for Regional Development of Serbia 2007-2012, p. 98 
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          Source: Data are taken from Table in Annex 1 
 
Foreign trade 
During the period 2001 – 2006, the foreign trade regarding those products was 
characterized by constant and growing trade deficit with the faster growth of 
imports (24.14%) than the exports (14.63%). The annual average share of those 
products in the total exports and imports accounted for 2.3%. 
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Table 5. Trade in Pharmaceuticals 2001-2006 in Serbia, annually  
(000 EURO) 
 
  
2001 2002 2003 2004 2005 2006 
Export 
growth 
(%) 
Import 
growth 
(%) 
Export 45,216 53,876 62,999 58,132 82,825 102,594 14.63  
Import 81,383 116,674 147,397 193,895 223,213 297,902  24.14 
Balance -36,167 -62,798 -84,398 -135,763 -140,388 -195,308   
Source: Statistical Office of the Republic of Serbia 
 
The biggest volume of foreign trade was recorded with the products from 
tariff group 3004 – medicaments prepared for the retail sale. During the period 
under review, the import grew twice faster and the trade deficit made the half of 
the total trade deficit in the foreign trade of pharmaceutical products. In the same 
time the two products from the tariff heading 30 (3004 32 10 00 and 3004 10 10 
00) are the only products from this group that recorded significant surplus in 
foreign trade. The tariff protection of these two products is not so significant, and 
also is not highly expressed in the initial offer.   
After the tariff group 3004, the second place are taking the products from the 
tariff group 2941 (antibiotics) and 3002 (blood) even though their trade volume is 
much lower. These products together the products from the tariff group 3004, in 
six years will contribute to the realization (80%) of trade deficit in trade of 
pharmaceutical products. Regarding the fact that products from the tariff group 
2941 are used as a row materials in the pharmaceutical industry, their current 
protection is 0% and in the initial offer the protection is increased only for one 
products (due to the harmonization with EU). Almost there is a same situation 
regarding the products from the tariff group 3002.  
Regarding the trade volume, there is still one group of products that distinct 
from the other pharmaceutical products. In average, the trade volume of those 
products recorded 8.6 mill. EURO and 90% concern the imports. Those products 
belong to the tariff group 3006.   
Generally speaking, the tariff protection of pharmaceutical products does not 
deviate significantly from the sector initiative requirement. The tariff protection 
expressed in the initial offer is ranging from 0% to 10% (only one product has a 
protection of 30% - pharmaceutical waste) and the average tariff protection 
accounts for 3.74% which is not so significantly different from the current level 
(1.7%). However, according to the Law on medicaments and medical devices, the 
legal persons have to fulfill the conditions prescribed and have a license for 
disposing the medicines for sale issued by the Ministry of Health and license 
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issued by the Ministry of Agriculture, Forestry and Water management in the case 
of veterinary medicaments. This measure regards the quality control, safety and 
efficiency of medicaments within aim of protecting people’s health. This measure 
also represents the non tariff barrier in trade of pharmaceutical products and 
medical devices.  
During the period 2001-2006, Serbia recorded high trade deficit in trade of 
pharmaceuticals. Average trade deficit during the period under review was around 
109 million EUR. 
 
Table 6. Trade in Pharmaceuticals 2001-2006, annually average (000 EURO) 
 
Average trade 2001-2006 000 EUR 
Export 67,607.00 
Import 176,744.00 
Trade Balance -109,137.00 
Source: Statistical Office of the Republic of Serbia 
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